BioVersys AG (SIX: BIOV) announced the first patient enrollment in its Phase 3 clinical trial for BV100, an experimental antibiotic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE